ATE287949T1 - Löslicher komplex morphogener proteine und zusammensetzungen davon - Google Patents

Löslicher komplex morphogener proteine und zusammensetzungen davon

Info

Publication number
ATE287949T1
ATE287949T1 AT93918529T AT93918529T ATE287949T1 AT E287949 T1 ATE287949 T1 AT E287949T1 AT 93918529 T AT93918529 T AT 93918529T AT 93918529 T AT93918529 T AT 93918529T AT E287949 T1 ATE287949 T1 AT E287949T1
Authority
AT
Austria
Prior art keywords
compositions
morphogenic proteins
soluble complex
soluble
proteins
Prior art date
Application number
AT93918529T
Other languages
English (en)
Inventor
William K Jones
Ronald F Tucker
David C Rueger
Hermann Oppermann
Engin Ozkaynak
Thangavel Kuberasampath
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Application granted granted Critical
Publication of ATE287949T1 publication Critical patent/ATE287949T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
AT93918529T 1992-07-31 1993-07-29 Löslicher komplex morphogener proteine und zusammensetzungen davon ATE287949T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92378092A 1992-07-31 1992-07-31
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/007189 WO1994003600A1 (en) 1992-07-31 1993-07-29 Morphogenic protein soluble complex and composition thereof

Publications (1)

Publication Number Publication Date
ATE287949T1 true ATE287949T1 (de) 2005-02-15

Family

ID=27363455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918529T ATE287949T1 (de) 1992-07-31 1993-07-29 Löslicher komplex morphogener proteine und zusammensetzungen davon

Country Status (8)

Country Link
EP (1) EP0652953B1 (de)
JP (3) JP3981405B2 (de)
KR (1) KR950702627A (de)
AT (1) ATE287949T1 (de)
AU (1) AU678380B2 (de)
CA (1) CA2141555C (de)
DE (1) DE69333745T2 (de)
WO (1) WO1994003600A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5610021A (en) * 1992-02-21 1997-03-11 Creative Biomolecules, Inc. Compositions and methods for identification and use of soluble complex forms of osteogenic proteins
WO1994010203A2 (en) * 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
CA2157387C (en) * 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
AU1180195A (en) * 1993-11-16 1995-06-06 Children's Medical Center Corporation Method of identifying a substance capable of inducing bone formation
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
ZA9711580B (en) * 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
WO1998050060A1 (en) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
EP2309261A1 (de) 1997-05-30 2011-04-13 Stryker Corporation Verfahren zur Beurteilung von Gewebemorphogenese und- aktivität
EP1037910A2 (de) * 1997-12-04 2000-09-27 Curis, Inc. Nachschutz der glatte muskulatur durch morphogenetische protein
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
AU2005229072A1 (en) * 2004-03-26 2005-10-13 Acceleron Pharma Inc. BMP-3 propeptides and related methods
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
EP1771557B1 (de) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3-Propeptide und damit zusammenhängende Verfahren
US7659250B2 (en) 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
ATE543833T1 (de) * 2005-12-22 2012-02-15 Janssen Biotech Inc Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
CA2652549A1 (en) * 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
WO2008014054A2 (en) * 2006-07-27 2008-01-31 Centocor, Inc. Bmp-7 variant compositions, methods and uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857456A (en) * 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
WO1992007073A1 (en) * 1990-10-18 1992-04-30 Creative Biomolecules, Inc. Osteogenic peptides
EP0601135B1 (de) * 1991-08-30 2005-11-02 Curis, Inc. Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
CA2157387C (en) * 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production

Also Published As

Publication number Publication date
JP3981405B2 (ja) 2007-09-26
AU4795193A (en) 1994-03-03
AU678380B2 (en) 1997-05-29
JP2007051162A (ja) 2007-03-01
JP4126321B2 (ja) 2008-07-30
JPH07509611A (ja) 1995-10-26
WO1994003600A1 (en) 1994-02-17
DE69333745T2 (de) 2005-12-29
DE69333745D1 (de) 2005-03-03
CA2141555C (en) 2007-03-27
EP0652953A1 (de) 1995-05-17
KR950702627A (ko) 1995-07-29
EP0652953B1 (de) 2005-01-26
CA2141555A1 (en) 1994-02-17
JP2008163028A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE287949T1 (de) Löslicher komplex morphogener proteine und zusammensetzungen davon
IL130190A0 (en) Methods and compositions for polypeptide engineering
AU5055593A (en) Antibodies specific for HIV
ATE180776T1 (de) Naphthylverbindungen, zwischenprodukte, zusammensetzungen und methoden
HUT69170A (en) 2-debenzoyl-2-acyl-taxol derivatives and methods for making same, and parmaceutical preparations kontaining them
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
NO973879D0 (no) Stent, og fremgangsmåte for fremstilling av samme
HRP950337A2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
DK0585943T3 (da) Opløselige ligander for CD40
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
BG102623A (en) New derivatives of benzoylguanadine, methods for their preparation and application for the manufacture of medicamentous forms
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
DE68914638T2 (de) Polyaluminosilikat-mikrogel, verfahren und zusammensetzung.
KR950700310A (ko) 헤테로트리사이클릭 유도체, 그의 제조방법 및 그를 함유하는 약제학적 조성물(heterotricyclic derivatives, process for their preparation and pharmaceutical compositions containing them)
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ITRM920506A0 (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
BG102771A (en) Diarylmethylidenfuran derivatives, method for their preparation and utilization as medicamentous forms
IT1290923B1 (it) Sacchetto e metodo per la produzione dello stesso.
ATE210460T1 (de) Zusammensetzungen, welche adp-ribosyltransferase- aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
DK229984A (da) 4-oxothiazolidin-2-yliden-acetamidderivater
PT951471E (pt) Inibidores cicloalquilo de farnesiltransferase de proteinas
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties